Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Shoshiro Oe"'
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 83:129-135
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 53:239-245
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 81:953-958
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 49:139-145
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 47:637-643
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 45:369-378
G-CSF高値を示した胃原発扁平上皮癌の1例を経験したので報告する.症例は66歳の男性で,全身倦怠感を主訴に来院し,内視鏡で胃上部後壁に約10cmの1型病変を指摘された.血清SCC抗原は130
Autor:
Jonas Larsson, Shoshiro Oe, Elizabeth A. Conner, Snorri S. Thorgeirsson, Eric R. Lemmer, Valentina M. Factor, Per Levéen, Stefan Karlsson
Publikováno v:
Hepatology. 40:1098-1105
Transforming growth factor beta (TGF-beta) is a potent inhibitor of hepatocyte proliferation in vitro and is suggested to be a key negative regulator of liver growth. To directly address the role of TGF-beta signaling in liver regeneration in vivo, t
Autor:
Shoshiro Oe, Hideaki Fujii, Takahisa Fujikawa, Yoshio Yamaoka, Hisaya Azuma, Tetsuro Hirose, Kentaro Yasuchika
Publikováno v:
Journal of Hepatology. 39:162-170
Background/Aims : Recent advances in stem cell research have revealed that hepatic stem/progenitor cells may play an important role in liver development and regeneration. However, a lack of detectable definitive markers in viable cells has hindered t
Autor:
Koichi Hasegawa, Yoshio Yamaoka, Hideaki Fujii, Hisaya Azuma, Takahisa Fujikawa, Tetsuro Hirose, Shoshiro Oe, Kentaro Yasuchika
Publikováno v:
Hepatology. 36:1488-1497
Autor:
Naoki, Uyama, Etsuro, Hatano, Yoji, Maetani, Hiroyoshi, Isoda, Toshiya, Shibata, Kojiro, Taura, Shoshiro, Oe, Masato, Naito, Kentaro, Yasuchika, Hideaki, Fujii, Iwao, Ikai, Shinji, Uemoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 35(5)
In this study we evaluated the efficacy and toxicity of transcatheter arterial chemoembolization (TACE) with Cisplatin (CDDP)-Lipiodol (LIP) suspension in 24 patients with advanced hepatocellular carcinoma (HCC). Eligibility criteria were as follows;